Shots:
- Phibro Animal Health has entered into a licensing agreement with Lighthouse Pharmaceuticals to develop & commercialize a therapeutic asset targeting periodontal health in companion animals
- As per the agreement, Phibro will obtain exclusive rights to develop, manufacture, and commercialize Lighthouse Pharma’s proprietary compound for canine periodontal care, though financial terms were not disclosed
- The compound, developed using gingipain inhibitor platform, has demonstrated favorable efficacy & safety in preclinical models
Ref: Phibro Animal Health | Image: Phibro Animal Health & Lighthouse Pharmaceuticals | Press Release
Related News:- Merck Animal Health Reports the US FDA’s Approval of Exzolt for Northern Fowl Mites
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
